Find a Clinical Trial
Is a clinical trial right for you? Search our database to find studies for which you may be eligible.
Phase I/Ib Study of AKT Inhibitor Ipatasertib with Chemoradiation for Locally Advanced Head and Neck Cancer
Study Type: Treatment
Phase: I
NCTID: NCT05172245
Principal Investigator:
Chris Lominska
Comparing Two Cisplatin Dosing Schedules Combined With Radiation for Patients With Advanced Head and Neck Cancer
Study Type: Treatment
Phase: II/III
NCTID: NCT05050162
Principal Investigator:
Chris Lominska
A Multicenter, Randomized, Double-blind, Placebo-Controlled, Phase III Study of Ficlatuzumab in Combination with Cetuximab in Participants with Recurrent or Metastatic R/M HPV-Negative Head and Neck Squamous Cell Carcinoma FIERCE-HN
A Phase II, Open-Label, Multicenter Study of INCAGN01876 in Combination With Immunotherapy in Participants With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma.
A Phase II, randomized, open-label, multicenter, clinical study to evaluate the safety and efficacy of lenvatinib monotherapy E7080/MK-7902 and pembrolizumab MK- 3475 plus lenvatinib combination therapy in participants with recurrent or metastatic head and neck squamous cell carcinoma R/M HNSCC who progress after immunotherapy PD-1/PD-L1 inhibitors
Phase 1b Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Repeated Doses of DB-020 in Patients Receiving Cisplatin
Pre-Operative Nutritional Intervention in Head and Neck Cancer
A Phase III Randomized Placebo-Controlled Double-Blind Clinical Study of Pembrolizumab Mk-3475 With or Without Lenvatinib E7080/Mk-7902 to Evaluate the Safety and Efficacy of Pembrolizumab and Lenvatinib as 1L Intervention in a PD-L1 Selected Population of Participants with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma R/M HNSCC LEAP-010
Phase III Randomized, Double-blind, Multicenter, Global Study of Monalizumab or Placebo in Combination with Cetuximab in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Previously Treated With an Immune Checkpoint Inhibitor.
A Phase II Randomized Trial of Adjuvant Therapy with Pembrolizumab after Resection of Recurrent/Second Primary Head and Neck Squamous Cell Carcinoma with High Risk Features
Study Type: Treatment
Phase: II
NCTID: NCT04671667
Principal Investigator:
Chris Lominska